Ropinirole 1 mg Tablets Recalled Nationwide for Manufacturing Process Deviations
Direct Rx is recalling Ropinirole 1 mg tablets nationwide due to manufacturing process deviations. Consult a pharmacist before stopping this medication.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II classification with manufacturing process deviations. No illnesses or injuries are reported in the source, making the hazard theoretical. This meets the rubric criterion for a risk-of-harm product where injury has not yet been reported.
Plain-English summary
Direct Rx is recalling Ropinirole, USP, 1 mg tablets nationwide. The affected product is lot 22JU2216 (expiration 8/31/23), packaged in 30-count bottles with NDC 72189-0364-30. Four bottles of this lot were distributed nationwide.
The recall was initiated due to current good manufacturing practice (cGMP) deviations. The firm voluntarily initiated the recall on March 13, 2023, and it was terminated on June 17, 2024.
Patients taking this medication should not stop treatment without consulting their healthcare provider or pharmacist. If you have this medication, contact your pharmacy or healthcare provider for guidance on how to proceed.
The recalled product
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot
- expiry: 22JU2216
- exp 8/31/23
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 11 recalled by Direct Rx under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 11 products in this recall →Related recalls
Same manufacturer · Direct Rx
See all →- ModerateDuloxetine 30 mg capsules recalled for impurity above FDA limits
FDA (Drugs) · 2026-07-01
- HighDirect Rx duloxetine 30 mg capsules exceed the interim nitrosamine limit
FDA (Drugs) · 2025-08-13
- HighDuloxetine delayed-release capsules exceed the interim nitrosamine impurity limit
FDA (Drugs) · 2025-08-13
- ModerateCiprofloxacin Ophthalmic Solution Recalled for Defective Container Cap
FDA (Drugs) · 2025-04-23
- HighGeneric Ibuprofen 800mg Recalled Due to Failed Impurity and Degradation Specifications
FDA (Drugs) · 2024-11-13
Same hazard · manufacturing defect
See all →- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-09-02
- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- HighKnee Prosthesis Trial Recall for Manufacturing Defect
FDA (Devices) · 2026-08-12
- HighUnited Orthopedic Corp. Recalls Femoral Valgus Offset Adaptors for U2 Total Knee System
FDA (Devices) · 2026-08-12
- HighU2 Total Knee System Femoral Valgus Adaptor Recall
FDA (Devices) · 2026-08-12